Company intelligence / Profile preview
Elios Therapeutics
Austin, Texas, United Stateslinkedin.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 3
01
Overview
Elios Therapeutics develops personalized therapeutic cancer vaccines using a proprietary delivery system to stimulate both innate and adaptive immunity. Their lead candidate, TLPLDC, has reached Phase 2 clinical development targeting metastatic melanoma and other solid tumors. The company focuses on addressing unmet needs in oncology through autologous immunotherapies designed to generate durable anti-tumor responses.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic cancer vaccines (autologous)immunotherapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Elios Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elios Therapeutics.